SUMMARY In a study designed to explain conflicting reports of hypermagnesaemia in schizophrenia, significantly higher concentrations of plasma-magnesium were found in phenothiazinetreated schizophrenic women than in normal women of the same age. This did not apply to men. Magnesium levels were inversely related to motor activity in untreated chronic schizophrenic men in hospital as well as in patients of both sexes receiving butyrophenone or phenothiazine derivatives. The magnesium concentration fell significantly when institutionalized schizophrenic and nonschizophrenic men were placed on neuroleptic medication. It is concluded that age, sex, pharmacotherapy, and level of activity all influence the metabolism of magnesium in schizophrenic subjects.
Significantly elevated magnesium concentrations in the plasma of schizophrenic subjects have been reported in some studies (Katzenelbogen and Snyder, 1943; Cade, 1964; Brackenridge and McDonald, 1969) but not in others (Gottfried and Willner, 1949; Masiak and Bernaskiewicz, 1965; Seal and Eist, 1967) . The significance of these conflicting reports is unclear for two sets of reasons: firstly, substantial differences in the clinical criteria required for a diagnosis of schizophrenia exist; secondly, a large number of variables are known to affect magnesium levels (Walser, 1967) . These facts make a study of any relationship between the two sets of factors possible only by defining the clinical criteria precisely and by controlling as many as possible of the variables known to affect magnesium levels.
We present here the results obtained over a threeyear period on patients defined according to the criteria indicated below.
SUBJECTS AND METHODS
SUBJECTS All psychiatric patients were free from known physical disease. Diagnostic criteria and clinical notes have been reported previously for patients with acute and chronic schizophrenia (Brackenridge and Jones, 1968; Whittingham, Mackay, Jones, and Davies, 1968; Brackenridge and McDonald, 1969; Jones, Davies, Buckle, Hanna, and Pikla, 1970) . Acutely-ill psychotic cases had been recently admitted to a hospital ward at the time of blood collection, while chronic patients had been confined to a mental hospital after an episodic course of illness. The criteria for diagnosis were: the presence of cardinal symptoms such as passivity-feelings or schizophrenic thought-disorder, a constellation of symptoms constituting one of the Kraepelin (1919) A mixed group of chronically-ill, non-schizophrenic hospital patients consisted of nine with Korsakoff's psychosis, eight with general paralysis of the insane, eight with mental retardation, five with chronic brain syndrome, four with alcoholic dementia, two with personality disorder, and one each with endogenous depression, Huntington's chorea, post-encephalitic and post-traumatic states. Twenty-one of these 40 were receiving drug treatment at the time of blood collection.
All patients were matched with normal control subjects for sex and within three years for age. Details have been given elsewhere (Brackenridge and Jones, 1968 ).
METHODS Male chronic schizophrenic patients were assessed for motor, social, and total activity by means of the Venables (1957) scale, and for structural preservation of speech, extent of hallucinations, delusions, ideas of reference, general information, and orientation for time and place using the scale of Harris, Letemendia, and Willems (1967) . Venous blood samples were drawn into tubes containing lithium heparin. Plasma-magnesium determinations were carried out by atomic-absorption spectrophotometry (Willis, 1960; Brackenridge and McDonald, 1969) .
Standard statistical methods were used, including Student's t test for independent and paired samples, product-moment and partial correlation coefficients, and analysis of variance. Calculations were performed on an Olivetti Programma 101 computer.
RESULTS
NORMAL SUBJECTS The mean (± SD) plasmamagnesium concentration in 86 healthy men aged 37-6 ± 18-1 years was 2-07 ± 0-18 mg/100 ml., while the mean in 60 healthy women aged 43 9 ± 23-8 years was 2 08 ± 0-18 mg/100 ml. Values were distributed normally in each group. A significantly positive correlation with age was found in females (r = 043, P < 0 001) and in both sexes combined (r = 0-28, P < 0 001), but not in males (r = 0-16, P> 0-1).
SCHIZOPHRENIC PATIENTS The magnesium levels in schizophrenic patients undergoing phenothiazine medication are presented in Table 1 . The mean concentrations in the men were not significantly higher than those in their control groups, whereas the female groups were appreciably hypermagnesaemic. Normal distribution curves were observed throughout.
Significant correlation coefficients between plasmamagnesium concentration and age were found in chronic female schizophrenic patients (r = 044, P < 0-05), all chronic patients (0 53, P < 0-001), all female patients (0 44, P < 0 001), and all patients (0-36, P < 0 001). Although a sex-effect appears to operate in Table 1 , the mean ages of the male and female groups differ appreciably. It was possible to match 18 acutely-ill patients of each sex closely for age. The mean plasma-magnesium level in the men (2-04 ± 0-22 mg/100 ml.) was lower than that in the women (2-11 ± 0-23 mg/100 ml.), but not significantly so. When these 18 pairs were supplemented by an additional 17 pairs of chronic schizophrenic patients, the male levels (2-06 ± 0-19 mg/100 ml.) became significantly lower (P < 0 05) than the female levels (2-17 ± 023 mg/100 ml. daily) and 20 were placed on a butyrophenone derivative (methylperidol, 14 mg twice daily). After seven weeks of this treatment blood samples were again taken. Plasma-magnesium concentrations were significantly lower (P < 0-01) after trifluoperazine therapy (2-13 ± 0-18 mg/100 ml.) than before (2-31 ± 0 21 mg/100 ml.). They were also (2-35 ± 0-13 mg/100 ml.) was not significantly renic higher than that in the untreated group of average erva-motor activity (2-24 ± 0-24 mg/100 ml.) comprising ,ause 50 % of the total. However, the level in the treated zssed underactive group (218 ± 0-16 mg/100 ml.) was icensignificantly higher than that in the treated average d the group (2-07 ± 0-17 mg/100 ml.) (P < 0-05) comdis-prising 60% of the total. )jects
Correlation coefficients between pre-and postf 22 treatment magnesium levels and age, period of but hospitalization, and motor, social, and total activity ,ated scores on the Venables scale were then calculated. n the Only motor activity and magnesium concentration f the before drug therapy were significantly correlated yper-(r = 0-034, P < 0-05). When the effects of age, ;igni-length of stay in hospital, and social activity were rsons allowed for, the partial correlation coefficient between magnesium level and motor activity became ables -0-40 (P < 0 02). The partial correlation coefficient and between magnesium levels before and after treatwere ment was 0-40 (P < 0-02) when the influence of )le 2. motor and social activities was eliminated. On no drugs 19 56-6 ± 7-8 56-6 ± 8-1 2-33 ± 0.24* 2-14 ± 0-21 <0-01 On phenothiazines 13 49 5 ± 14-3 48-9 ± 13-9 2-16 ± 0-19* 2-06 + 0-22 NS On other drugs 8 51-8 ± 15-5 51-3 ± 16-4 2-31 ± 0-14 209 ± 0-16 <0-02
On any drugs 21 50-4 ± 14-4 49-8 ± 14-5 2-22 ± 0-18 2-07 ± 0-20 <0-02 Treated and untreated 40 53 4 + 12-0 53-1 ± 12-3 2-27 i 0-22 2-10 ± 0-20 <0-001 *These mean levels differ significantly (P < 0-05).
than did the controls. Those who were having phenothiazine medication did not have significantly higher levels. In addition magnesium levels were significantly lower in phenothiazine-treated men than in men not having any medication (P < 0-05). Comparison with the data of Table 2 , which details findings with schizophrenic patients, indicates that magnesium levels of untreated schizophrenic and non-schizophrenic men did not differ significantly and levels of schizophrenic and non-schizophrenic men receiving phenothiazine derivatives also failed to differ significantly. As with the schizophrenic patients, smoking was without effect on the plasmamagnesium concentrations of non-schizophrenic males regardless of drug status.
DISCUSSION
Human plasma-magnesium levels appear to have no diurnal rhythm and are unaffected by normal eating habits and carbohydrate intake (Metz and MoursLaroche, 1955; Stern and Lewis, 1960; Wallach, Cahill, Rogan, and Jones, 1962) . That some effect of institutionalization is a relevant factor in this study is suggested by the finding that all but the phenothiazine-treated non-schizophrenics had high magnesium levels. Diet seems an unlikely cause of hypermagnesaemia in view of the experiment by Heaton and Parsons (1961) . They supplemented a normal diet with magnesium salts to provide an increased intake of up to 500 mg per day but found no significant rise in the plasma levels of two males and two females, the increased absorption from the intestine being balanced by a similar increase in urinary excretion. Institutional factors are likely to be only a partial explanation, since, among hospitalized patients, women had significantly higher levels of magnesium than did men. It is known that men fail to retain a magnesium load more readily than women under certain dietary conditions (Seelig, 1964 Evidence on the influence of age is conflicting: Keating, Jones, Elveback, and Randall (1969) found no effect while Roberts (1967) described a positive correlation in women. Frank and Carr (1957) reported significant differences between serum concentrations at the menses and at the intermenstrual period. They also demonstrated an annual cycle. Neither of these rhythms is likely to have introduced a bias in the present study. Thus the chronic schizophrenic women, who displayed the most pronounced hypermagnesaemia, were of post-menopausal age. Further, as samples were collected from patients and healthy donors throughout the course of three years, an annual rhythm should not have produced any uncontrolled errors.
The present investigation throws some light on previously published results, some of which appeared contradictory. Thus while confirming the hypermagnesaemia reported by Cade (1964) in acutely-ill female patients, and supporting other observations (Katzenelbogen and Snyder, 1943; Brackenridge and McDonald, 1969) , the normal values found by Seal and Eist (1967) in chronic schizophrenic men receiving phenothiazine drugs concur with our results. In the study of Masiak and Bernaskiewicz (1965) equal numbers of males and females were involved. In view of the sex differences in magnesium levels it is difficult to compare the present findings with the normal levels they encountered in early and chronic cases. The Polish workers found their chronic patients to possess significantly higher serum magnesium concentrations than subjects in an early phase before and after treatment. Again this is hard to corroborate for, while analysis of data in Table 1 shows the levels in chronic patients to exceed those in the acute patients, the values in their control subjects also differ significantly.
Considerable evidence for an association between activity and magnesium metabolism in schizophrenia has been presented in the present study but little has been reported on their relationship in other conditions. The hypermagnesaemia observed in hypothyroidism (Wallach et al., 1962) is associated with motor retardation. Conversely, Whang and Wagner (1966) found that exercise also caused an increased serum-magnesium level which was ascribed to an intracellular movement of water. It is unlikely that the hypermagnesaemia of schizophrenia arises by this mechanism because, at least in female geriatric patients (Brackenridge and McDonald, 1969) , it is associated with a normal erythrocyte concentration of the metal. The increasing extent of withdrawal observed in patients passing from normality through acute to chronic psychotic phases is consistent with the corresponding increases in magnesium concentrations cited in Table 1 . Whether this is cause or effect is unclear. The magnesium levels are more elevated in female patients than in males, and, because the increase persists when subjects are matched for age, it is not age-dependent. Chronic deteriorated schizophrenic women are not known to be generally more withdrawn than their male counterparts, so it is plausible that a sexrelated factor is also operating.
It seems clear from the results in Tables 2 and 3 that neuroleptic drugs depress the plasma-magnesium level in both schizophrenic and non-schizophrenic patients; in the former an associated rise in activity occurs. Methylperidol and trifluoperazine were equally effective in decreasing magnesium concentrations in chronic schizophrenic men. In the nonpsychotic group, from a variety of medication only neuroleptic drugs lowered the concentration significantly. Whether this is related to mode of action or is simply an epiphenomenon is uncertain.
